The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
Finance

Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health

SEP 16, 2026
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
Breathing Engineered Bacteria: A New Approach to Treating Lung Disease
GMO & Synbio

Breathing Engineered Bacteria: A New Approach to Treating Lung Disease

AUG 10, 2026
Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data
Clinical & Manufacturing

Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data

AUG 7, 2026
Gut fungi may hold the key to treating Asthma worldwide
Pharma & Human Health

Gut fungi may hold the key to treating Asthma worldwide

JUN 26, 2026
Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial
Clinical & Manufacturing

Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial

JUN 8, 2026
Redefining Probiotic Manufacturing Through Advanced Nutrient Solutions
Biotics and Supplements

Redefining Probiotic Manufacturing Through Advanced Nutrient Solutions

JUN 3, 2026
Microbiotica Announces Positive Phase 1b Results for Precision Microbiome Co-Therapy in Advanced Melanoma
Pharma & Human Health

Microbiotica Announces Positive Phase 1b Results for Precision Microbiome Co-Therapy in Advanced Melanoma

MAY 18, 2026
Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug
Finance

Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug

MAY 8, 2026
Engineered commensals for metabolic modulation of the gut-liver-brain axis
Gut-Brain Axis

Engineered commensals for metabolic modulation of the gut-liver-brain axis

MAY 4, 2026
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS
Clinical & Manufacturing

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS

APR 30, 2026